支气管哮喘免疫机制与相关靶向药物研究进展  

Research Progress in Immune Mechanism of Bronchial Asthma and Related Targeted Drugs

作　　者：李娇娇 陈佳禾 金蕊 LI Jiaojiao;CHEN Jiahe;JIN Rui(Department of Pediatrics,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210036,China)

机构地区：[1]南京医科大学第一附属医院儿科,南京210036

出　　处：《医学综述》2023年第20期4148-4153,共6页Medical Recapitulate

基　　金：国家自然科学基金(82270068)。

摘　　要：支气管哮喘(简称哮喘)是一种以慢性气道炎症和高反应性为特征的呼吸系统疾病,其典型症状为呼气性呼吸困难,可伴有气促、胸闷或咳嗽,严重影响儿童身体健康。哮喘的发病机制复杂,目前认为哮喘是由环境、遗传与免疫共同作用的结果,不同的患者可具有不同的病理生理学机制。近年来,随着对哮喘免疫机制不断深入的研究,不同类型炎症途径上新靶点的涌现,使哮喘靶向治疗成为哮喘新药研发和治疗的热点。分子靶向治疗有望成为哮喘治疗的新方案。Bronchial asthma(short for asthma)is a respiratory disease characterized by chronic airway inflammation and hyper-responsiveness,and the typical symptoms are expiratory dyspnea,which may be accompanied by shortness of breath,chest tightness or cough,seriously affecting the health of children.The pathogenesis of asthma is complex.It is currently believed that asthma is the result of the combined action of environment,heredity and immunity,and different patients have different pathophysiological mechanisms.In recent years,with the continuous in-depth research on the immune mechanism of asthma,new targets of different types of inflammatory pathways have emerged,making targeted therapy of asthma become a hotspot in the novel drug development and treatment for asthma.Molecular targeted therapy is expected to become a new approach to asthma.

关 键 词：支气管哮喘 发病机制 靶向治疗 

分 类 号：R456[医药卫生—治疗学]